• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Standard Lithium to Attend 37th Annual Roth Conference

    3/5/25 8:00:31 AM ET
    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals
    Industrials
    Get the next $A alert in real time by email

    VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium") (TSXV:SLI) (NYSE:A), a leading near-commercial lithium developer today announced senior leadership will participate in the upcoming 37th Annual Roth Conference.

    Event  37th Annual Roth Conference
    DateMarch 16 – 18, 2025
    LocationThe Laguna Cliffs Marriott Resort & Spa, Dana Point, CA
      

    Salah Gamoudi, Chief Financial Officer and Chris Lang, Director of Finance will be hosting one-on-one meetings during the conference. Interested investors should contact their Roth representative or Standard Lithium Investor Relations at [email protected].

    About Standard Lithium Ltd.

    Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The Company prioritizes projects characterized by the highest quality resources, robust infrastructure, skilled labor, and streamlined permitting. Standard Lithium aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated Direct Lithium Extraction ("DLE") and purification process. The Company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. In partnership with global energy leader Equinor, Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and actively exploring promising lithium brine prospects in East Texas. Additionally, the Company is advancing the Phase 1A project in partnership with LANXESS Corporation, a brownfield development project located in southern Arkansas. Standard Lithium also holds an interest in certain mineral leases in the Mojave Desert in San Bernardino County, California.

    Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol "SLI"; and on the Frankfurt Stock Exchange under the symbol "S5L". Please visit the Company's website at www.standardlithium.com.

    Media Contact:

    Chris Lang

    Director of Finance

    Standard Lithium Ltd.

    +1 604 409 8154

    [email protected] 

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain certain "Forward-Looking Statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target, "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to intended development timelines, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.



    Primary Logo

    Get the next $A alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $A
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    Agilent Technologies Inc.
    $A
    8/28/2024$157.00Overweight
    Wells Fargo
    Agilent Technologies Inc.
    $A
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    Agilent Technologies Inc.
    $A
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    Agilent Technologies Inc.
    $A
    6/3/2024$135.00Hold
    Jefferies
    Agilent Technologies Inc.
    $A
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    Standard Lithium Ltd.
    $SLI
    2/16/2024Outperform
    BMO Capital Markets
    Agilent Technologies Inc.
    $A
    12/13/2023$140.00Outperform
    Wolfe Research
    More analyst ratings

    $A
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Gonsalves Rodney (Amendment)

      4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      10/20/23 1:07:25 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      9/29/23 4:03:46 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    $SLI
    SEC Filings

    See more
    • SEC Form 6-K filed by Standard Lithium Ltd.

      6-K - STANDARD LITHIUM LTD. (0001537137) (Filer)

      5/29/25 8:45:55 AM ET
      $SLI
      Major Chemicals
      Industrials
    • Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/28/25 4:06:14 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 6-K filed by Standard Lithium Ltd.

      6-K - STANDARD LITHIUM LTD. (0001537137) (Filer)

      5/27/25 4:57:02 PM ET
      $SLI
      Major Chemicals
      Industrials

    $A
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilent upgraded by Barclays with a new price target

      Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

      2/10/25 6:55:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Agilent with a new price target

      Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

      8/28/24 7:20:29 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent upgraded by Citigroup with a new price target

      Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

      7/10/24 7:22:08 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Smackover Lithium's South West Arkansas Project Receives Royalty Rate Approval From the Arkansas Oil and Gas Commission

      LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of

      5/29/25 8:30:27 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Names August Specht as Chief Technology Officer

      Agilent Technologies Inc. (NYSE:A) today announced August Specht, Ph.D., has been named the company's Chief Technology Officer. Specht, previously vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific, will join Agilent on June 9. "We are thrilled to welcome August Specht to the Agilent team as we further accelerate the pace of innovation in an ever-changing world through our Ignite Transformation," said Padraig McDonnell, Agilent president and CEO. "August brings more than 25 years of experience designing, developing, and marketing analytical instruments, software, and consumables that support scientific advancement around the worl

      5/28/25 8:30:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    $SLI
    Financials

    Live finance-specific insights

    See more
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces Cash Dividend of 24.8 Cents per Share

      Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans

      5/21/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard Lithium Reports Fiscal First Quarter 2025 Results

      VANCOUVER, British Columbia, May 09, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, today announced its financial and operating results for the three month fiscal period ended March 31, 2025. "2025 will be a pivotal year for us, marked by several key milestones that will shape the future of Standard Lithium, our joint venture, and impact the industry as a whole," said David Park, Chief Executive Officer and Director of Standard Lithium. "We started with a strong first quarter by finalizing our $225 million grant from the US Department of Energy, advancing our subsurface understanding th

      5/9/25 8:30:02 AM ET
      $SLI
      Major Chemicals
      Industrials

    $A
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP and CFO Mcmahon Robert W. covered exercise/tax liability with 3,499 shares, decreasing direct ownership by 2% to 168,754 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/27/25 2:43:34 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Soriot Pascal was granted 1,677 shares (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/23/25 10:39:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Soriot Pascal claimed no ownership of stock in the company (SEC Form 3)

      3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/23/25 10:37:37 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

      SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 1:27:37 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 11:54:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/4/24 10:57:57 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    $SLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

      Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

      4/24/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard Lithium Appoints Karen G. Narwold to the Board of Directors

      VANCOUVER, British Columbia, March 19, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is pleased to announce the appointment of Karen G. Narwold, NACD.DC as an independent member of its board of directors. Robert Cross, Non-Executive Chairman of the Board of Directors, commented, "The Standard Lithium Board is excited to welcome Karen as an independent director. Karen brings over 30 years of executive leadership experience within the manufacturing and chemicals space, including most recently as Chief Administrative Officer, General Counsel and Corporate Secretary at Albemarle Corporatio

      3/19/25 8:30:46 AM ET
      $SLI
      Major Chemicals
      Industrials
    • Standard Lithium Appoints Paul Collins to the Board of Directors

      VANCOUVER, British Columbia, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI) (FRA:S5L), a leading near-commercial lithium company, is pleased to announce the appointment of Paul Collins as an independent member of its board of directors. Robert Cross, Non-Executive Chairman of the Board of Directors, commented, "On behalf of the Standard Lithium Board, I am delighted to welcome Paul as an independent director. He brings over 35 years of advisory and investment banking experience in industrials, chemicals and energy to the Board. Throughout his career, Paul served as a trusted advisor to executives and boards on strategic

      12/10/24 8:00:00 AM ET
      $SLI
      Major Chemicals
      Industrials